Home › Niet-kleincellige longkanker › Ohio › Akron
Niet-kleincellige longkanker klinische studies in Akron, OH
22 studies voor Niet-kleincellige longkanker zoeken deelnemers op locaties in en rond Akron (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruterenFase 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 mijl verwijderd
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruterenFase 3
- Aultman Health Foundation, Canton · 21 mijl verwijderd
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RekruterenFase 3
- Akron General Medical Center, Akron
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RekruterenFase 3
- Aultman North, North Canton · 15 mijl verwijderd
- Aultman Massillon, Massillon · 20 mijl verwijderd
- Aultman Orrville Hospital, Orrville · 21 mijl verwijderd
- en nog 2
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RekruterenFase 3
- Research Site, Canton · 21 mijl verwijderd
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RekruterenFase 3
- Aultman Hospital, Canton · 21 mijl verwijderd
Pan-tumor MRD Study
RekruterenObservatieonderzoek
- Gabrail Cancer Center, Canton · 21 mijl verwijderd
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekruterenFase 2/3
- Gabrail Cancer Center Research, Canton · 21 mijl verwijderd
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
RekruterenFase 2
- Gabrail Cancer Center, Canton · 21 mijl verwijderd
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruterenFase 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 mijl verwijderd
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RekruterenFase 1/2
- Gabrail Cancer Center Research, Canton · 21 mijl verwijderd
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
RekruterenFase 3
- Gabrail Cancer Center, Canton · 21 mijl verwijderd
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
RekruterenFase 2
- Gabrail Cancer and Research Center, Canton · 21 mijl verwijderd
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruterenFase 2
- Cleveland Clinic Mercy Hospital, Canton · 21 mijl verwijderd
- Aultman Health Foundation, Canton · 21 mijl verwijderd
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Aultman Health Foundation, Canton · 21 mijl verwijderd
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2
- Aultman Health Foundation, Canton · 21 mijl verwijderd
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruterenFase 2/3
- Aultman Health Foundation, Canton · 21 mijl verwijderd
GEMINI-NSCLC: NSCLC Biomarker Study
RekruterenObservatieonderzoek
- Aultman Hospital, Canton · 21 mijl verwijderd
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RekruterenFase 1
- Gabrail Cancer & Research Center, Canton · 21 mijl verwijderd
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekruterenFase 1/2
- Research Site 138, Canton · 21 mijl verwijderd
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RekruterenFase 1/2
- Gabrail Cancer Center Research, Canton · 21 mijl verwijderd
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
RekruterenFase 1/2
- Gabrail Cancer Research Center, Canton · 21 mijl verwijderd
Niet-kleincellige longkanker studies in andere steden
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Andere studies in Akron
- Longkanker16 studies
- Kanker (alle vormen)13 studies
- Borstkanker13 studies
- Prostaatkanker9 studies
- Acute myeloïde leukemie8 studies
- Melanoom8 studies
- Kleincellige longkanker8 studies
- Metastatische kanker8 studies
- Colorectale kanker8 studies
- Steatotische leveraandoening7 studies
- Endometriumkanker6 studies
- Eierstokkanker6 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.